Cargando…

A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer

INTRODUCTION: This is a retrospective analysis to assess the safety and efficacy of abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC) patients treated at tertiary care institute. MATERIALS AND METHODS: The clinical records of mCRPC patients treated with AA at our tert...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joshi, Amit, Shrirangwar, Sameer, Noronha, Vanita, Sable, Nilesh, Agarwal, Archi, Popat, Palak, Bhattacharjee, Atanu, Prabhash, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	ORIGINAL ARTICLE: Genitourinary Cancers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956584/ https://www.ncbi.nlm.nih.gov/pubmed/31956615 http://dx.doi.org/10.4103/sajc.sajc_433_18

Ejemplares similares

Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis
por: Agarwala, Vivek, et al.
Publicado: (2018)

Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
por: Patil, Vijay, et al.
Publicado: (2021)

Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
por: Yekedüz, Emre, et al.
Publicado: (2023)

Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters
por: Shariftabrizi, Ahmad, et al.
Publicado: (2023)

(177)Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art
por: AlSadi, Rahaf, et al.
Publicado: (2022)

Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study
por: Stein, Mark N, et al.
Publicado: (2022)

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2022)

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
por: Mehra, Niven, et al.
Publicado: (2022)

Management of testicular tumours in patients with undescended testes— a challenging but rewarding task: experience from a tertiary care cancer centre in India
por: Tongaonkar, Arnav, et al.
Publicado: (2023)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer
por: Vargas, Carlos E., et al.
Publicado: (2018)

Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
por: Patil, Vijay M., et al.
Publicado: (2016)

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
por: Noronha, Vanita, et al.
Publicado: (2017)

Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center
por: Ramaswamy, Anant, et al.
Publicado: (2017)

Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Freeman, Meredith N, et al.
Publicado: (2022)

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer
por: Sena, Laura A., et al.
Publicado: (2020)

Prostate cancer survival estimates: An application with piecewise hazard function derivation
por: Bhattacharjee, Atanu, et al.
Publicado: (2019)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
por: Noronha, Vanita, et al.
Publicado: (2016)

Geriatric oncology: The need of the hour
por: Joshi, Amit, et al.
Publicado: (2013)

A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer
por: Joshi, Amit, et al.
Publicado: (2016)

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2016)

Stereotactic body radiation therapy for medically inoperable, clinically localized, urothelial carcinoma of the renal pelvis: A case report
por: Evans, Jaden D., et al.
Publicado: (2017)

Salvage image guided radiation therapy to the prostate after cryotherapy failure
por: Hopper, Austin B., et al.
Publicado: (2017)

Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
por: Akthar, Adil S., et al.
Publicado: (2018)

Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images
por: Tong, Yubing, et al.
Publicado: (2018)

Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial
por: McDonald, Andrew M., et al.
Publicado: (2018)

Transitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions
por: Solanki, Abhishek A., et al.
Publicado: (2018)

The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2N0R0 Prostate Cancer? A Multi-Institutional Study
por: Kraus, Ryan Douglas, et al.
Publicado: (2018)

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
por: Welch, Brian T., et al.
Publicado: (2018)

Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience
por: Lee, Howard J., et al.
Publicado: (2018)

Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer
por: Schad, Michael D., et al.
Publicado: (2019)

Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer
por: Pinitpatcharalert, Attapol, et al.
Publicado: (2019)

Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States
por: Scherzer, Nickolas D., et al.
Publicado: (2019)

Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data
por: Weg, Emily S., et al.
Publicado: (2019)

Pathologic Complete Response After Chemoradiation of a Massive Primary Urethral Carcinoma
por: Singh, Tanmay, et al.
Publicado: (2019)

Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking
por: Chaurasia, Avinash R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cutmbupn2emo4ijb6se44m4f3c